Bavarian Nordic’s chikungunya vaccine secures EMA fast-track
23 Feb 2024
Clinical ResultPhase 3VaccinePhase 1Fast Track
Preview
Source: Pharmaceutical Technology
Hot on the heels of dropping its cancer vaccine programme, Bavarian Nordic has secured a win in more familiar territory, after the big pharma received an accelerated assessment from the EMA for its chikungunya vaccine.
Bavarian Nordic said it aims to submit a marketing authorisation application to the agency in the first half of 2024 for its CHIKV VLP candidate. The accelerated assessment means that the EMA could review the application in 150 days, rather than the normal 210.
Accelerated assessments are issued to drug products of major public health and therapeutic innovation.
Bavarian Nordic’s CEO Paul Chaplin said that the company also plans to submit a biologics licence application (BLA) to the US Food and Drug Administration (FDA) later this year.
Chikungunya is a mosquito-borne disease that causes fever and severe joint pain. Death from the virus is rare, but joint pain can sometimes last up to months and is debilitating.
See Also:PepGen earns FDA fast track designation for myotonic dystrophy type 1 candidate
Preview
Source: Pharmaceutical Technology
Bavarian Nordic’s revenue soars post-mpox outbreaks
Preview
Source: Pharmaceutical Technology
Bavarian Nordic’s CHIKV VLP has demonstrated positive results from two successfully completed Phase III trials which enrolled just over 3,500 health participants. Both studies met their primary endpoints of inducing high levels of neutralising antibodies against the disease after 22 days.
The trial in adolescents and adults aged 12 to 64 years (NCT05072080) showed that 98% of vaccines had antibodies while the trial in adults older than 65 (NCT05349617) had antibodies confirmed in 82% of individuals. Bavarian Nordic reported mild to moderate adverse events, with the most common being muscle pain, fatigue, and headache.
Valneva’s Ixchiq became the world’s first licensed chikungunya vaccine when it was approved by the FDA in November 2023. There is currently no vaccine approved for the disease in Europe, although Bavarian Nordic will have to catch up with Valneva who had a marketing application for its candidate accepted by the EMA under accelerated assessment in November 2023.
Bavarian Nordic, which reported its most successful financial year in 2023, recently streamlined its portfolio. The drugmaker shelved its immune-oncology project, which had a vaccine candidate dubbed TAEK-VAC-HerBy in a Phase I trial. While announcing financial results, Bavarian Nordic said the project had “reached a stage where clinical expansion and further investments would be required”.
The company redirected resources and R&D efforts to its infectious diseases programmes, the therapy area in which the big pharma has enjoyed success. Bavarian Nordic’s revenue jumped from a surge in sales of its Jynneos vaccine for smallpox / mpox along with its travel health range.
In May 2023, Bavarian Nordic strengthened its travel vaccine portfolio and acquired Emergent’s travel health business in a deal worth up to $380m.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.